上皮癌-话题@MedSci

#上皮癌#

151篇内容 | 3332人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539285, encodeId=a4171539285ef, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）, objectType=article, longId=79710, objectId=edd4e9710ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd4e9710ea, replyNumber=0, likeNumber=73, createdTime=2016-10-12, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd4e9710ea, moduleTitle=Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd4e9710ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539284, encodeId=e57c153928413, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=2016EAU指南——非肌肉浸润性膀胱尿路上皮癌（更新版）发布, objectType=article, longId=79589, objectId=e073e95890d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e073e95890d, replyNumber=0, likeNumber=67, createdTime=2016-10-10, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e073e95890d, moduleTitle=2016EAU指南——非肌肉浸润性膀胱尿路上皮癌（更新版）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e073e95890d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539283, encodeId=6c801539283e3, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, objectType=article, longId=68717, objectId=7e3c68e17a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3c68e17a3, replyNumber=0, likeNumber=71, createdTime=2016-05-21, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3c68e17a3, moduleTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e3c68e17a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539282, encodeId=cb2115392826d, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=35, createdTime=2016-03-08, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539281, encodeId=8dea15392812a, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素, objectType=article, longId=61453, objectId=921a6145366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921a6145366, replyNumber=0, likeNumber=84, createdTime=2016-01-01, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921a6145366, moduleTitle=BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921a6145366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539280, encodeId=90811539280ac, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=PLoS One：基因的遗传变异可导致卵巢上皮癌的风险, objectType=article, longId=52370, objectId=8d65523e0a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d65523e0a0, replyNumber=0, likeNumber=57, createdTime=2015-07-16, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d65523e0a0, moduleTitle=PLoS One：基因的遗传变异可导致卵巢上皮癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d65523e0a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539279, encodeId=1e5715392e92c, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, objectType=article, longId=51776, objectId=99ee51e7685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99ee51e7685, replyNumber=0, likeNumber=59, createdTime=2015-06-09, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99ee51e7685, moduleTitle=ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99ee51e7685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539278, encodeId=7f4815392e889, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO 2015：膀胱尿路上皮癌免疫治疗进展, objectType=article, longId=51706, objectId=081c51e0688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=081c51e0688, replyNumber=0, likeNumber=103, createdTime=2015-06-07, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=081c51e0688, moduleTitle=ASCO 2015：膀胱尿路上皮癌免疫治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=081c51e0688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539277, encodeId=73db15392e7e0, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响, objectType=article, longId=48845, objectId=b0c248845ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0c248845ee, replyNumber=0, likeNumber=65, createdTime=2015-04-02, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0c248845ee, moduleTitle=Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0c248845ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539276, encodeId=d08b15392e672, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=晚期尿路上皮癌的二线治疗探索, objectType=article, longId=47674, objectId=62064e67496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62064e67496, replyNumber=0, likeNumber=75, createdTime=2015-03-05, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62064e67496, moduleTitle=晚期尿路上皮癌的二线治疗探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62064e67496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539275, encodeId=f55c15392e544, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=JCO：卡铂方案对某些尿路上皮癌疗效更好, objectType=article, longId=3660, objectId=c85b366097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c85b366097, replyNumber=0, likeNumber=65, createdTime=2012-01-08, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c85b366097, moduleTitle=JCO：卡铂方案对某些尿路上皮癌疗效更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c85b366097)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

上皮癌

2020-05-29

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）

2016-10-12

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

2016EAU指南——非肌肉浸润性膀胱尿路上皮癌（更新版）发布

2016-10-10

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌

2016-05-21

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好

2016-03-08

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素

2016-01-01

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

PLoS One：基因的遗传变异可导致卵巢上皮癌的风险

2015-07-16

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展

2015-06-09

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO 2015：膀胱尿路上皮癌免疫治疗进展

2015-06-07

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响

2015-04-02

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

晚期尿路上皮癌的二线治疗探索

2015-03-05

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

JCO：卡铂方案对某些尿路上皮癌疗效更好

2012-01-08

科室
- - 订阅+
  - 更多科室
工具
服务